Biogen Inc. surged after an Alzheimer’s drug known as BAN2401 phase 2b showed positive results in a large clinical trial, raising hopes for early disease’s patients.
According to Biogen and its Japanese partner Eisai Co. announcement that the highest treatment dose of BAN2401, an anti-amyloid beta protofibril antibody, began to show statistically significant clinical benefit as early as 6 months including at 12 months.
“The study is a bright spot — if a tenuous one — in the search for a treatment for Alzheimer’s, where more than 100 experimental drugs have failed” Bloomberg reports. “Drugmakers have persisted in part because of the size of the potential market — as much as $30 billion in the U.S. alone, according to Sanford C. Bernstein & Co. analysts.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at firstname.lastname@example.org.
The success of BAN2401 will depend on the details of the data, set to be presented at a medical meeting, according to Bloomberg Intelligence analyst Sam Fazeli.”
While the ultimate outcome remains far from certain, the study is a bright spot — if a tenuous one — in the search for a treatment for Alzheimer’s, where
In December 2017, the study did not achieve its primary outcome measure which was designed to enable a potentially more rapid entry into Phase 3 development based on Bayesian analysis at 12 months of treatment.
Following the predefined study protocol, the blinded study continued with a comprehensive final analysis on treatment conducted at 18 months. Upon the final analysis at 18 months using predefined conventional statistical method, the study did demonstrate a statistically significant slowing of disease progression on the key clinical endpoint after 12 months of treatment in patients receiving the highest treatment dose (10 mg/kg twice a month) as compared to placebo. The study is ongoing with a further follow-up assessment at 21 months.
Detailed results of the study will be presented at future scientific conferences.